Readers following the Nexavar compulsory licensing story will know that multi-national pharma companies had expected the US to defend their patents. In fact, as the SpicyIP blog notes, the US reaction has been muted. US trade policy is a complex issue but this does seem a surprisingly calm reaction from the world’s foremost protector of IP.
You are here: / / U.S. seemingly unworried by India’s actions on medical patents
This site uses Akismet to reduce spam. Learn how your comment data is processed.